• Participant must be at least 12 years of age inclusive, at the time of signing the informed consent.

• Participants must have AD as defined by the American Academy of Dermatology Consensus Criteria for 1 year or longer at baseline.

• Participant must have documented history (within 6 months prior to screening visit), of inadequate response (including inadequate efficacy or medical inadvisability) to topical treatments and/or inadequate response to systemic therapies (within 12 months prior to screening visit).

• Eczema Area Severity Index (EASI) of 16 or higher at baseline visit/Visit 2.

• Validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 3 or 4 at baseline visit/Visit 2.

• AD involvement of 10% or more of body surface area (BSA) at baseline visit/Visit 2.

• Weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) of ≥ 4 at baseline visit/Visit 2.

• Able and willing to comply with requested study visits and procedures.

• Body weight must be greater than or equal to 25 kg.

• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants must not be pregnant or breastfeeding.